Cambridge Healthtech Institute’s 6th Annual
Rational Combination Cancer Immunotherapy
Data Drives Combinatorial Strategies and Successes
August 27-28, 2018
As the discovery of new cancer immunotherapies continues to grow, developers are identifying promising patient-specific neoantigens and finding new ways to modulate the immune response beyond or in combination with checkpoint inhibitors. Numerous clinical studies are exploring the application of these therapeutics in combinations with traditional and experimental agents. Thus, emerging data from these preclinical models and clinical trials demonstrate the need for massive data analytics to provide actionable answers for patients. CHI’s 6th Annual Rational Combination Cancer Immunotherapy conference takes a forward-looking perspective on the design of drug products and treatment progressions and builds on the knowledge arising from these exploratory trials.
KEYNOTE PRESENTATION: Rational Combination of Immunotherapy, It Is Science, Not Logic
Samir Khleif, MD, Immunotherapy Scientist, Jeannie and Tony Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University
Forward and Reverse Translational Approaches to Augment Response to Anti-PD1 Therapy
Sarah Javaid, PhD, Associate Principal Scientist, Genetics and Pharmacogenomics, Merck
Leveraging Systems Biology and Machine Learning to Improve IO Biomarkers and Inform Combination Therapies
Janusz Dutkowski, PhD, CEO, Data4Cure, Inc.
Leveraging Clinical and Preclinical Targeted Therapy Biomarker Data to Inform Combinations with Immunotherapy
Matthew Meyer, PhD, Senior Investigator II, Oncology Pharmacology, Novartis Institutes for BioMedical Research, Inc.
Multiple “Immune Defects” in Pancreatic Cancer: How Do We Find the Right Combination of Immunotherapy?
Lei Zheng, MD, PhD, Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program/Bloomberg-Kimmel Institute for Cancer Immunotherapy (BKI), The Pancreatic Cancer Precision Medicine Program, Graduate Program in Cellular & Molecular Medicine, The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Graduate Program in Molecular and Cellular Medicine, Johns Hopkins University School of Medicine
Hypomethylating Agents in Combination with Immune Checkpoint Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Naval Daver, MD, Associate Professor, Leukemia Department, MD Anderson Cancer Center
Translational Immuno-Oncology in the Age of Big Data – A Bioinformatics Perspective
Yuriy Gusev, PhD, Associate Professor, Innovation Center for Biomedical Informatics (ICBI), Georgetown University
A Dynamic View of Cancer Dynamics and Drug Resistance
Doron Levy, PhD, Professor, Department of Mathematics, University of Maryland
For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
For partnering and sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286